To define numerically the clinical severity of facioscapulohumeral muscular dystrophy (FSHD), we developed a protocol that quantifies muscle weakness by combining the functional evaluation of six muscle groups affected in this disease. To validate reproducibility of the protocol, 69 patients were recruited. Each patient was evaluated by at least five neurologists, and an FSHD severity score was given by each examiner. The degree of agreement among clinicians' evaluations was measured by kappa-statistics. Nineteen subjects received a score between 0 and 1, 9 had a score between 2 and 4, 20 received a score between 5 and 10, and 8 had a score between 11 and 15. Of the 13 subjects with D4Z4 alleles within the normal range (ranging from 10 to 1...
Background and aims: For the last 20 years, the diagnosis of facioscapulohumeral muscular dystrophy ...
Background: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined. Metho...
OBJECTIVE: To add quantitative muscle MRI to the clinical trial toolbox for facioscapulohumeral musc...
To define numerically the clinical severity of facioscapulohumeral muscular dystrophy (FSHD), we dev...
To define numerically the clinical severity of facioscapulohumeral muscular dystrophy (FSHD), we dev...
Based on the 7-year experience of the Italian Clinical Network for FSHD, we revised the FSHD clinica...
OBJECTIVE: To evaluate facial weakness in patients with FSHD to better define clinical signs, and pi...
International audienceFacioscapulohumeral muscular dystrophy (FSHD) is among the most prevalent musc...
Background and objectives Facioscapulohumeral muscular dystrophy (FHSD) is a debilitating inherited ...
Muscular dystrophy (MD) comprises a group of diseases characterized by progressive muscle weakness t...
Background and aims: For the last 20 years, the diagnosis of facioscapulohumeral muscular dystrophy ...
Background: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined. Metho...
OBJECTIVE: To add quantitative muscle MRI to the clinical trial toolbox for facioscapulohumeral musc...
To define numerically the clinical severity of facioscapulohumeral muscular dystrophy (FSHD), we dev...
To define numerically the clinical severity of facioscapulohumeral muscular dystrophy (FSHD), we dev...
Based on the 7-year experience of the Italian Clinical Network for FSHD, we revised the FSHD clinica...
OBJECTIVE: To evaluate facial weakness in patients with FSHD to better define clinical signs, and pi...
International audienceFacioscapulohumeral muscular dystrophy (FSHD) is among the most prevalent musc...
Background and objectives Facioscapulohumeral muscular dystrophy (FHSD) is a debilitating inherited ...
Muscular dystrophy (MD) comprises a group of diseases characterized by progressive muscle weakness t...
Background and aims: For the last 20 years, the diagnosis of facioscapulohumeral muscular dystrophy ...
Background: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined. Metho...
OBJECTIVE: To add quantitative muscle MRI to the clinical trial toolbox for facioscapulohumeral musc...